Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated 
Advanced Non-small Cell Lung Cancer

Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated 
Advanced Non-small Cell Lung Cancer

Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in m...

Full description

Bibliographic Details
Main Authors: Bowen LI, Jianchao XUE, Yadong WANG, Zhicheng HUANG, Naixin LIANG, Shanqing LI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2022-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
epidermal growth factor receptor
antiangiogenic drugs
combined modality therapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.41

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.41

Similar Items